ARS Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SPRY in the last 7 days.
No SEC Form 4 filings for $SPRY in the last 30 days.
See all $SPRY insider activity →ARS Pharmaceuticals (SPRY) director Richard Lowenthal plans to sell 840 shares under Rule 144, following recent sales of 125,000 shares in August 2026 totaling $786,390. The sale is related to a stock option exercise dated September 2, 2026, and will be facilitated by Morgan Stanley.
ARS Pharma (SPRY) reported Q2 2026 U.S. net product revenue of $26.2M, with total market share reaching 5%, up from 2.5% YoY. Neffy's market share in targeted areas hit 8%, driven by 16,000+ unique prescribers. The company aims to expand into the CSU market and expects cash flow breakeven by late 2027. Total revenue was $33.7M, with operating expenses at $95.1M. ARS plans to reduce SG&A and R&D expenses by over 40% in the second half of 2026.
ARS Pharmaceuticals (SPRY) reported Q2 2026 earnings, with Neffy's US market share doubling to 5% YoY. CEO Donn Casale outlined priorities including targeted commercial efforts and cost cuts. Revenue was $33.7M, with operating expenses at $95.1M. The company plans to reduce spending by over 40% in H2 2026 and aims for cash flow breakeven by late 2027. Short interest is high at 31.17% of the float.
Recent SPRY coverage spans earnings, market movers and financial news.
Insider sale may signal negative sentiment, potentially exerting slight downward pressure on the stock.
Strong revenue growth and cash position, but elevated SG&A; guidance suggests tighter cost discipline and path to cash‑flow breakeven by 2027.
Earnings miss cost base but show market-share gains for neffy; guidance indicates tighter spending.
Negative sentiment due to lack of coverage and higher expense outlook.
The print and revised cost plan shift the near-term risk-reward toward neffy adoption and faster path to cash-flow breakeven by end-2027.
AlphAI scores every news story that mentions SPRY with an AI model for sentiment and relevance, and aggregates insider trades from ARS Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARS Pharmaceuticals (SPRY) director Richard Lowenthal plans to sell 840 shares under Rule 144, following recent sales of 125,000 shares in August 2026 totaling $786,390. The sale is related to a stock option exercise dated September 2, 2026, and will be facilitated by Morgan Stanley.
1 min readARS Pharma (SPRY) reported Q2 2026 U.S. net product revenue of $26.2M, with total market share reaching 5%, up from 2.5% YoY. Neffy's market share in targeted areas hit 8%, driven by 16,000+ unique prescribers. The company aims to expand into the CSU market and expects cash flow breakeven by late 2027. Total revenue was $33.7M, with operating expenses at $95.1M. ARS plans to reduce SG&A and R&D expenses by over 40% in the second half of 2026.
3 min readARS Pharmaceuticals (SPRY) reported Q2 2026 earnings, with Neffy's US market share doubling to 5% YoY. CEO Donn Casale outlined priorities including targeted commercial efforts and cost cuts. Revenue was $33.7M, with operating expenses at $95.1M. The company plans to reduce spending by over 40% in H2 2026 and aims for cash flow breakeven by late 2027. Short interest is high at 31.17% of the float.
2 min readARS Pharmaceuticals (SPRY) shares fell 23% after-hours as it reported no new major commercial insurance coverage for Neffy effective July 1. The company is in negotiations with payers and secured additional Medicaid coverage. ARS lowered 2026 operating expense guidance to $248M and reaffirmed cash flow break-even target for 2027. Neffy had 120,000 U.S. patients in Q1 and $72.2M in 2025 net sales, 86% of total revenue.
2 min readARS Pharmaceuticals (SPRY) reported Q2 2026 revenue of $33.7M, up from $15.7M a year earlier, driven by $26.2M U.S. net product revenue from neffy. Net loss widened to $62.3M ($0.63/share). The company cut broad consumer ads, targeted high-volume prescribers, appointed Meg Smith CCO, and expects H2 2026 SG&A and R&D of $114M-$126M.
6 min readARS Pharmaceuticals (NASDAQ: SPRY) shares fell about 7% after an FDA-related setback and a CVS Caremark coverage delay that pushed broader coverage to at least January 2027, according to the article. It also cites a securities class action alleging misstatements tied to the timing. The piece notes LTM revenue near $84M, cash about $144M, and quarterly operating cash burn around $61M.
6 min readUS stock index futures edged higher after the S&P 500 and Nasdaq 100 hit record levels. Tech and AI-related shares led, with Sandisk up in premarket after JPMorgan’s overweight rating. Reuters said the BOJ is considering a September rate hike. Several single-stock moves followed earnings, guidance, tariffs, and analyst actions, including AVAV, AEHR, SPRY, CAPR, NU, RDDT, and GLOB.
7 min readARS Pharmaceuticals (NASDAQ:SPRY) said it expanded its field sales force and will target high-value prescribers, noting neffy has about 8% market share in the field-targeted universe versus ~1% in non-targeted. Commercial coverage is 90%. Q2 operating expenses were $95.1M. ARS expects cash-flow breakeven by end-2027 and Phase IIb CSU interim data in Q1 2027.
6 min readARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results $26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5%
7 min readARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001671858 0001671858 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2026 Date of Report (Date of earliest event report
2 min read
